INVESTORS

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer
NEW HAVEN, Conn. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Anthony S. Gibney to the position of Executive Vice President and Chief Business Officer, effective immediately. Mr.
View HTML
Toggle Summary Achillion Reports Second Quarter 2018 Financial Results
- Global phase 2 clinical programs for ACH-4471 continue to expand in PNH and C3G - - Completed dosing phase 1 clinical study of ACH-5228 and initiated phase 1 study of ACH-5548 - - June 30, 2018 cash position $295.8 million - NEW HAVEN, Conn. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Achillion
View HTML
Toggle Summary Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D
-  Additional clinical compounds expand factor D portfolio opportunities - NEW HAVEN, Conn. , July 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a clinical-stage pharmaceutical company focused on developing small molecule inhibitors of factor D in the complement
View HTML
Toggle Summary Achillion to Present at the 2018 JMP Securities Life Sciences Conference
NEW HAVEN, Conn. , June 14, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt , President and Chief Executive Officer of Achillion, will present at the 2018 JMP Securities Life Sciences Conference on Thursday, June 21, 2018 , at 9:00 a.m.
View HTML
Toggle Summary Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress
- Oral presentation discussing ACH-4471 and interim biomarker data from the ongoing 14-day Phase 2 study in C3G - - Poster presentation detailing in vitro data showing no significant reduction in serum bactericidal activity with factor D inhibition - NEW HAVEN, Conn.
View HTML
Toggle Summary Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference
NEW HAVEN, Conn., May 04, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43 rd Annual Health Care Conference on Tuesday, May 8,
View HTML
Toggle Summary Achillion Reports First Quarter 2018 Financial Results and Management Transition
 - Plans for clinical data in C3 glomerulopathy (C3G) and for paroxysmal nocturnal hemoglobinuria (PNH) remain on track for 2018 -  - Joseph Truitt appointed Chief Executive Officer - NEW HAVEN, Conn., May 02, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
View HTML
Toggle Summary Achillion to Present at the Barclays Global Healthcare Conference
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a corporate overview at the Barclays Global Healthcare Conference on Thursday, March 15, 2018, at 11:15
View HTML
Toggle Summary Achillion Raises Awareness for C3 Glomerulopathy With Launch of WeC3G™ Initiative as Part of Rare Disease Day 2018
February 28, 2018 is the 11 th Annual Rare Disease Day Achillion sponsors initiative to help shine the light on C3G to raise awareness and understanding of this rare, chronic disease affecting the kidneys NEW HAVEN, Conn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
View HTML
Toggle Summary Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy
NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the complement alternative pathway, today announced that the European Medicines Agency (EMA) Committee
View HTML